References
- WHO Technical Reports No 498. International drug monitoring: the role of national centres. World Health Organization; Geneva: 1972
- Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, editor. Textbook of adverse drug reactions. Oxford University Press, Oxord; 1977. p. 44
- Winterstein AG, Sauer BC, Hepler CD, Poole C. Preventable drug-related hospital admissions. Ann Pharmacother 2002;36(7-8):1238-48
- Hakkarainen KM, Hedna K, Petzold M, Hägg S. Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions – a meta-analysis. PLoS One 2012;7(3):e33236
- Guidelines for the development of measures to combat counterfeit medicines. WHO, Geneva; 1999. Available from: www.who.int/medicines/publications/counterfeitguidelines/en/
- The importance of pharmacovigilance. WHO, Geneva; 2002. Available from: http://apps.who.int/medicinedocs/pdf/s4893e/s4893e.pdf
- The Global Fund. Available from: www.theglobalfund.org/en/ [Last accessed 4 February 2015]
- UNITAID. Available from: www.unitaid.org/ [Last accessed 4 February 2015]
- UNICEF. Available from: www.unicef.org/ [Last accessed 4 February 2015]
- Gavi. Available from: www.gavi.org/about/ [Last accessed 4 February 2015]
- PEPFAR. Available from: www.pepfar.gov/ [Last accessed 4 February 2015]
- Bill & Melinda Gates Foundation. Available from: www.gatesfoundation.org/ [Last accessed 4 February 2015]
- Dodoo A. WAHO and drug safety. Uppsala Rep 2010;50:16
- Minimum Requirements for a Functional Pharmacovigilance System. WHO, Geneva. Available from: www.who.int/medicines/areas/quality_safety/safety_efficacy/PV_Minimum_Requirements_2010_2.pdf?ua=1 [Last accessed 4 February 2015]
- Osakwe A. Nigeria adopts national policy. Uppsala Reports 61, April 2013, Uppsala Monitoring Centre. Available from: http://who-umc.org/graphics/27578.pdf [Last accessed 4 February 2015]
- Eritrean National Pharmacovigilance Policy, State of Eritrea. Ministry of Health; Asmara: 2014
- FDA Philippines. Available from: www.fda.gov.ph/issuances/153551-administrative-order-no-2011-0009 [Last accessed 4 February 2015]
- Assessment of medicines regulatory systems in sub-Saharan African countries, An overview of findings from 26 assessment reports. WHO; Geneva: 2010
- Patel KJ, Kedia MS, Bajpai D, et al. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study. BMC Clin Pharmacol 2007;7:8
- Benkirane R, Pariente A, Achour S, et al. Prevalence and preventability of adverse drug events in a teaching hospital: a cross-sectional study. Eastern Mediterranean Health J 2009;15:1145-55
- Gyllensten H, Jönsson AK, Rehnberg C, Carlsten A. How are the costs of drug-related morbidity measured? A systematic literature review. Drug Saf 2012; 10.2165/11597090-000000000-00000 0114-5916/12/0000-0000/$49.95/0
- Biswas P. Pharmacovigilance in Asia. J Pharmacol Pharmacother 2013;4:7-19
- Zhang L, Wong LYL, He Y, Wong ICK. Pharmacovigilance in China: current situation, successes and challenges. Drug Saf 2014;37(10):765-70
- Available from: www.lareb.nl/whocc [Last accessed 7 February 2015]
- Dollen MZ. Pharmacovigilance Legislation: The impact of what is happening in Europe. Ther Innov Regul Sci 2014;48:190-9
- Good Pharmacovigilance Practices. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp [Last accessed 7 February 2015]
- Anonymous. European Pharmacovigilance: increasingly outsourced to drug Companies. Prescrire International 2014;23:302-7
- Pharmacovigilance guidelines. Available from: www.who-umc.org/DynPage.aspx?id=127878&mn1=7347&mn2=7252&mn3=7253&mn4=7745 [Last accessed 16 March 2015]
- Pharmacovigilance guidelines. Available from: www.who-umc.org/DynPage.aspx?id=97223&mn1=7347&mn2=7252&mn3=7254 [Last accessed 17 March 2015]
- Centre Anti Poison et de pharmacovigilance du Maroc. Available from: www.capm.ma/index.php [Last accessed 7 February 2015]
- Wilbur K. Pharmacovigilance in the Middle East; A survey of 13 Arabic-speaking countries. Drug Saf 2013;36:25-30
- PPB Pharmacovigilance Newsletter, December 2012. http://pharmacyboardkenya.org/?page_id=442 [Last accessed 7 February 2015]
- Pirmohamed M, Atuah KN, Dodoo AN, Winstanely P. Pharmacovigilance in developing countries; Requires collaboration between stakeholders to develop novel models of funding. BMJ 2007;335:462
- Babigumira JB, Stergachis A, Choi HL, et al. A framework for assessing the economic value of pharmacovigilance in low- and middle-income countries. Drug Saf 2014; doi 10.1007/s40264-014-014
- Available from: www.who.int/3by5/progressreportJune2005/en/ [Last accessed 8 May 2015]
- A practical handbook on the pharmacovigilance of antiretroviral medicines. WHO, Geneva 2009. Available from: www.who.int/hiv/pub/pharmacovigilance/handbook/en/ [Last accessed 8 May 2015]
- The Safety of Medicines in Public Health Programmes: Pharmacovigilance an essential tool. WHO; Geneva: 2006
- A practical Handbook on the Pharmacovigilance of Antimalarial Medicines. WHO; Geneva: 2009
- A practical Handbook on the Pharmacovigilance of medicines used in the treatment of tuberculosis. WHO; Geneva: 2012
- Pal SN, Duncombe C, Falzon D, Olsson S. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf 2013;36:75-81
- Bassi PU, Osakwe AI, Isah A, et al. Safety of Artemisinin-Based Combination Therapies in Nigeria: A Cohort Event Monitoring Study. Drug Saf 2013;36:747-56
- Dodoo ANO, Fogg C, Nartey ET, et al. Profile of Adverse Events in Patients Receiving Treatment for Malaria in Urban Ghana: A Cohort-Event Monitoring Study. Drug Saf 2014;37:433-48
- Global Manual on Surveillance of Adverse Events Following Immunization. Available from: www.who.int/vaccine_safety/publications/aefi_surveillance/en/ [ Last accessed 7 February 2015]
- Available from: www.who.int/vaccine_safety/en/ [Last accessed 7 February 2015]
- Available from: https://docs.gatesfoundation.org/documents/SSWG%20Final%20Report%2011%2019%2013_designed.pdf [Last accessed 7 February 2015]
- Ndagije H, Nambasa V, Namagala E, et al. Targeted Spontaneous Reporting of suspected renal toxicity in patients undergoing Highly Active Anti-Retroviral Therapy in two public health facilities in Uganda. Drug Saf 2015;38(4):395-408
- Sharon Pandian S, Kang G. The Antenatal and Infant Monitoring System: Promoting AEFI Reporting in Difficult Environments. An innovative approach using interactive voice response (IVR) technology. GVSI Bulletin 2015;7:3
- Jajere F. Rapid consumer reports. Uppsala Reports 2014;65:16
- who-pvafrica.org/index.php/med-spina [Last accessed 8 March 2015]
- Available from: www.who.int/hinari/about/en/ [Last accessed 7 February 2015]
- Moore N, Biour M, Paux G, et al. Adverse drug reaction monitoring: doing it the French way. Lancet 1985;2(8463):1056-8
- Commission of the European Communities, Brussels 2008. Available from: www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/sec/2008/2671/COM_SEC(2008)2671_EN.pdf [Last accessed 7 February 2015]
- Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother 2013;4:73-7
- China Food and Drug Administration. 2012 Annual Report of National Adverse Drug Reaction Monitoring, Beijing. 2013;4
- Available from: www.pharmaceuticalpolicy.nl/PhD%20Program.html [Last accessed 8 March 2015]
- Beckmann J, Hagemann U, Bahri P, et al. Teaching Pharmacovigilance: the WHO-ISoP Core Elements of a Comprehensive Modular Curriculum. Drug Saf 2014;37(10):743-59
- Hazell L, Shakir SAW. Under-reporting of adverse drug reactions - a systematic review. Drug Saf 2006;29(5):385-96
- Olsson S, Pal SN, Stergachis A, Couper M. Pharmacovigilance activities in 55 low- and middle-income countries a questionnaire-based analysis. Drug Saf 2010;33(8):689-703
- Isah AO, Pal SN, Olsson S, et al. Specific features of medicines safety and pharmacovigilance in Africa. Therap Adv Drug Saf 2012;3(1):25-34
- Vadiya S.S, Guo J.J, Heaton P, Steinbuch M. Overview and comparison of postmarketing drug safety surveillance in selected developing and well-developed Countries Drug. Inf J 2010;44:519-33
- Anonymous. WHO Pharmacovigilance Indicators. WHO; Geneva: 2015; In press
- Olsson S. The role of the WHO programme on international drug monitoring in coordinating worldwide drug safety efforts. Drug Saf 1998;19:1-10
- Pal S, Dodoo A, Mantel A, Olsson S. Pharmacovigilance and Safety of Medicines, In The World Medicines Situation Report, WHO, Geneva. 2011. Available from: http://apps.who.int/medicinedocs/documents/s18771en/s18771en.pdf [Last accessed 9 March 2015]
- WHO Programme Members. Available from: www.who-umc.org/DynPage.aspx?id=100653&mn1=7347&mn2=7252&mn3=7322&mn4=7442 [Last accessed 7 March 2015]
- Safety Monitoring of Medicinal Products: Guidelines for setting up and running a pharmacovigilance Centre. Uppsala Monitoring Centre; Uppsala: 2000
- WHO Guidelines on safety monitoring of herbal medicines in pharmacovigilance systems. WHO; Geneva: 2004
- Available from: http:/WHO-pvafrica.org [Last accessed 8 March 2015]
- Available from: http://pvtoolkit.org [Last accessed 7 February 2015]
- Available from: www.who.int/medicines/publications/newsletter/en/ [Last accessed 7 February 2015]
- Comprehensive Assessment of Pharmacovigilance Systems and their Performance in Sub-Saharan Africa 2012. Available from: http://siapsprogram.org/publication/comprehensive-assessment-of-pharmacovigilance-systems-and-their-performance-in-sub-saharan-africa/ [Last accessed 7 February 2015]
- Comparative Analysis of Pharmacovigilance Systems in Five Asian Countries. 2014. Available from: http://siapsprogram.org/publication/comparative-analysis-of-pharmacovigilance-systems-in-five-asian-countries/. [Last accessed 7 February 2015]
- Strengthening Pharmaceuticals Systems (SPS) Programme 2009. Indicator –Based Pharmacovigilance Assessment Tool: Manual for Conducting Assessmentsd in Developing Countries. Submitted to the U.S. Agency for International Development by the SPS Programme. Arlington, VA: Management Sciences for Health; 2009
- Available from: www.paho.org/hq/index.php?option=com_content&view=article&id=1592&Itemid=40147 [Last accessed 8 March 2015]
- van Hunsel FPAM. The contribution of direct patient reporting to pharmacovigilance. thesis Groningen: Rijsuniversiteit Groningen; 2011
- Avery AJ, Anderson C, Bond CM, et al. Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess 2011;15:20
- Hartigan-Go K. Empowering consumers as contributors for health product safety: lessons from the Philippines. Drug Saf 2015;38(4):329-35